Medicare has included Botox (onabotulinumtoxinA, AbbVie/Allergan Aesthetics) on its list of 15 drugs eligible for price negotiation under the Inflation Reduction Act, effective 2026. This marks the first time a neuromodulator enters the negotiation cohort, reflecting Medicare's targeting of high-utilization, high-cost therapeutics.
For medspas and aesthetic practices, the immediate impact is indirect: Medicare covers Botox only for FDA-approved therapeutic indications (chronic migraine, overactive bladder, spasticity), not cosmetic use. However, negotiated Medicare pricing typically influences commercial payer benchmarks within 6–12 months. If Medicare secures a significant price reduction, commercial plans may demand similar discounts, pressuring practice acquisition costs and manufacturer rebate programs (Alle, Aspire).